Proficio Capital Partners LLC Purchases New Position in Omnicell, Inc. (NASDAQ:OMCL)

Proficio Capital Partners LLC acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 34,637 shares of the company's stock, valued at approximately $1,542,000. Proficio Capital Partners LLC owned about 0.07% of Omnicell as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of OMCL. Victory Capital Management Inc. increased its position in shares of Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after purchasing an additional 377,883 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after buying an additional 699,925 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its position in Omnicell by 27.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company's stock worth $49,742,000 after acquiring an additional 243,353 shares during the period. Geode Capital Management LLC boosted its stake in shares of Omnicell by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock worth $48,176,000 after acquiring an additional 2,877 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Omnicell by 3.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company's stock worth $27,431,000 after purchasing an additional 21,157 shares in the last quarter. Institutional investors own 97.70% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. StockNews.com upgraded Omnicell from a "hold" rating to a "buy" rating in a research report on Thursday, March 6th. Wells Fargo & Company reduced their target price on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Benchmark reaffirmed a "buy" rating and set a $62.00 price target on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. reduced their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday. Finally, Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research note on Monday, January 6th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Omnicell currently has a consensus rating of "Hold" and a consensus target price of $51.00.

Omnicell Price Performance

OMCL stock traded up $1.20 during mid-day trading on Monday, hitting $35.14. The company had a trading volume of 380,908 shares, compared to its average volume of 497,546. The company has a market capitalization of $1.64 billion, a price-to-earnings ratio of 130.15, a P/E/G ratio of 7.53 and a beta of 0.85. The company has a 50-day moving average price of $39.77 and a 200 day moving average price of $42.90. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.